Del Baldo Francesca, Corsini Andrea, Bresciani Francesca, Pergolese Valeria, Tirelli Isabella, Tardo Antonio Maria, Fracassi Federico
Department of Veterinary Medical Sciences, Alma Mater Studiorum-University of Bologna, Bologna, Italy.
Department of Veterinary Science, University of Parma, Parma, Italy.
J Vet Intern Med. 2025 Sep-Oct;39(5):e70222. doi: 10.1111/jvim.70222.
Velagliflozin is a sodium-glucose cotransporter 2 inhibitor licensed for the treatment of diabetes mellitus (DM) in cats, but its use in cats with hypersomatotropism is not described.
HYPOTHESIS/OBJECTIVES: To describe the use of velagliflozin in cats with DM and hypersomatotropism.
Eight client-owned cats with DM and hypersomatotropism treated with velagliflozin.
Retrospective multicentric case series. Clinical data, including diabetic clinical score, insulin dose, and continuous glucose monitoring-derived metrics were compared between the last follow-up before velagliflozin introduction (T0) and the first (T1) and last (T2) follow-ups after velagliflozin introduction.
Diabetic clinical score improved in 6/8 cats after velagliflozin initiation. Median daily insulin dose decreased from 1.9 U/kg (range 0.8-7.1) at T0 to 0.5 U/kg (0-2.3) at T1 (median difference [MD] = -1.2 U/kg; 95% CI: -5.2 to 0.5; p = 0.02). Mean glucose was lower both at T1 (207 mg/dL, 96-326) and T2 (273 mg/dL, 155-350) than at T0 (435 mg/dL, 298-477; MD = -177 mg/dL, 95% CI: -238 to -92, p = 0.008 and MD = -113 mg/dL, 95% CI: -280 to -18, p = 0.03, respectively). Percentage of time in range was higher at T1 (71%, 21-98) and T2 (41%, 14-100) than at T0 (3%, 0-32; MD = 61%, 95% CI: 21 to 80, p = 0.008 and MD = 34%, 95% CI: 2 to 98, p = 0.03, respectively). Velagliflozin allowed for insulin discontinuation in two cats. One cat developed diabetic ketoacidosis on day 143, and one cat had acute kidney injury.
Velagliflozin improved diabetic control in cats with DM and hypersomatotropism, either in combination with insulin or as monotherapy.
维格列净是一种钠-葡萄糖协同转运蛋白2抑制剂，已获许可用于治疗猫的糖尿病（DM），但尚未描述其在患有肢端肥大症的猫中的应用。
假设/目标：描述维格列净在患有DM和肢端肥大症的猫中的应用。
8只由客户拥有的患有DM和肢端肥大症并接受维格列净治疗的猫。
回顾性多中心病例系列。比较了引入维格列净前的最后一次随访（T0）与引入维格列净后的第一次（T1）和最后一次（T2）随访之间的临床数据，包括糖尿病临床评分、胰岛素剂量和持续葡萄糖监测得出的指标。
6/8只猫在开始使用维格列净后糖尿病临床评分有所改善。每日胰岛素剂量中位数从T0时的1.9 U/kg（范围0.8 - 7.1）降至T1时的0.5 U/kg（0 - 2.3）（中位数差异[MD] = -1.2 U/kg；95%置信区间：-5.2至0.5；p = 0.02）。T1（207 mg/dL，96 - 326）和T2（273 mg/dL，155 - 350）时的平均血糖均低于T0时（435 mg/dL，298 - 477；MD = -177 mg/dL，95%置信区间：-238至-92，p = 0.008；MD = -113 mg/dL，95%置信区间：-280至-18，p = 0.03）。血糖在目标范围内的时间百分比在T1（71%，21 - 98）和T2（41%，14 - 100）时高于T0时（3%），0 - 32；MD = 61%，95%置信区间：21至80，p = 0.008；MD = 34%，95%置信区间：2至98，p = 0.03）。维格列净使两只猫停用了胰岛素。一只猫在第143天发生糖尿病酮症酸中毒，一只猫出现急性肾损伤。
维格列净可改善患有DM和肢端肥大症的猫的糖尿病控制情况，无论是与胰岛素联合使用还是作为单一疗法。
